Eisai Co Ltd

New Eisai data shows anti‑tau antibody etalanetug reduces tau PET signal in some DIAD patients and a subcutaneous Leqembi launch targets Japan, boosting AD treatment access and convenience.

Discover how Eis Co.’s subcutaneous Leqembi (lecanemab) filings in Japan & the U.S. aim to accelerate Alzheimer’s therapy access, boost market share, and secure IP protection.

Read how Eisai’s Leqembi Iqlik could change Alzheimer’s care with at‑home injections and the implications for FDA approval, pricing, and market growth.

Shares of Eisai surge 6.4% as Nikkei rebounds, driven by strong biotech pipeline—Aduhelm, Lenvima, Inovelge—and upbeat market expectations for rate cuts.

Eisai Co., Ltd. has received FDA fast-track designation for its investigational Alzheimer’s disease treatment, a move that could accelerate its development and approval process, and position the company as a leader in the neurodegenerative disease m…

Eisai Co Ltd’s stock price surged 4.07% to a new high after the US FDA approved its Alzheimer’s treatment, LEQEMBI IQLIK, for maintenance dosing, marking a significant milestone for the company.

Eisai Co Ltd’s stock price has surged to a 52-week high due to the success of its Alzheimer’s disease treatment, Leqembi, which has shown sustained benefits over a four-year period.

Eisai Co Ltd reports a 15.62% increase in quarterly revenue, driven by expansion of its product portfolio and increased market presence.

Eisai Co Ltd reports a 15.62% increase in revenue for the quarter, with significant growth in profit and operating profit, and a positive outlook for the full year.

Eisai’s Alzheimer’s disease treatment, LEQEMBI, continues to drive growth and innovation, with strong sales and positive clinical data suggesting a potential upward trend in the company’s stock price.